The Biden Administration said Wednesday that it has secured agreements with Vertex Pharmaceuticals and bluebird bio for their sickle cell disease gene therapies to be the first in a new access model from the Centers for Medicare and Medicaid Services. The voluntary...
Collaboration will combine Vyriad’s lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ROCHESTER, Minn., Nov. 20, 2024 /PRNewswire/ — Vyriad, Inc., a clinical-stage biotechnology company developing the next...
WALTHAM, Mass., Sept. 24, 2024 /PRNewswire/ — Nanomosaic, the multiplex and multi-omic marker analysis company, today announced major technical and commercial milestones for its Tessie system and assays optimized for gene therapy applications, evidencing the...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has partnered with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P...
Through Pfizer Ignite, Acepodia will gain access to Pfizer’s resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer Ignite will also provide strategic advisory support for...
